Zenas BioPharma, Inc. (ZBIO) Stock Analysis & Investment Frameworks

Zenas BioPharma, Inc. (ZBIO) stock analysis on Invetso. Review Zenas BioPharma, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Zenas BioPharma, Inc. Company Overview

Zenas BioPharma, Inc. Key Financial Metrics

About Zenas BioPharma, Inc.

Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.

Zenas BioPharma, Inc. Investment Frameworks

Invetso analyzes Zenas BioPharma, Inc. (ZBIO) across the following frameworks:

Explore More ZBIO Research